BlackRock
STLN

BlackRock’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

BlackRock’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$13.6M Buy
4,415,867
+510,534
+13% +$1.57M ﹤0.01% 3309
2025
Q4 		$13.9M Buy
3,905,333
+470,458
+14% +$1.74M ﹤0.01% 3293
2025
Q3 		$12M Buy
3,434,875
+127,971
+4% +$438K ﹤0.01% 3360
2025
Q2 		$6.78M Buy
3,306,904
+3,044,554
+1,160% +$7.61M ﹤0.01% 3616
2025
Q1 		$299K Buy
262,350
+8,759
+3% +$6.78K ﹤0.01% 4529
2024
Q4 		$78.4K Buy
253,591
+651
+0.3% +$169 ﹤0.01% 4841
2024
Q3 		$82.7K Buy
252,940
+48,126
+23% +$19.9K ﹤0.01% 4713
2024
Q2 		$94.2K Buy
204,814
+55,383
+37% +$47.3K ﹤0.01% 4720
2024
Q1 		$236K Sell
149,431
-88,415
-37% -$168K ﹤0.01% 4551
2023
Q4 		$485K Hold
237,846
– – ﹤0.01% 4431
2023
Q3 		$333K Buy
237,846
+88,415
+59% +$91.5K ﹤0.01% 4533
2023
Q2 		$82.2K Sell
149,431
-774,486
-84% -$410K ﹤0.01% 4979
2023
Q1 		$626K Sell
923,917
-677,367
-42% -$864K ﹤0.01% 4478
2022
Q4 		$2.64M Buy
1,601,284
+71,634
+5% +$201K ﹤0.01% 4011
2022
Q3 		$7.08M Buy
1,529,650
+771,555
+102% +$4.54M ﹤0.01% 3600
2022
Q2 		$3.84M Buy
+758,095
New +$5.52M ﹤0.01% 3943

Other funds holding STLN

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
KWM
Kanen Wealth Management Coconut Creek, Florida $278M AUM 38.85% 1-Year Est. Return
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $117M AUM 26.5% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $690M AUM 57.88% 1-Year Est. Return
CP
CenterBook Partners Greenwich, Connecticut $1.86B AUM 24.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BlackRock's STLN Position: Q1 2026 in Review

BlackRock increased its Starling Oncology Institute, Inc. Common Stock (STLN) stake by 13% in Q1 2026, buying an estimated $1.57M and bringing the position to 4,415,867 shares worth $13.6M. The position accounts for ﹤0.01% of the portfolio, ranked #3309.

BlackRock first reported a position in STLN in Q2 2022 and has held it in 16 quarters since. The position peaked at $13.9M in Q4 2025. 115 funds tracked by Wall St. Rank hold STLN as of Q1 2026.

  • BlackRock held 4,415,867 shares of Starling Oncology Institute, Inc. Common Stock worth $13.6M as of Q1 2026.
  • BlackRock bought 510,534 Starling Oncology Institute, Inc. Common Stock shares in Q1 2026, an estimated $1.57M.
  • Starling Oncology Institute, Inc. Common Stock made up ﹤0.01% of BlackRock's portfolio in Q1 2026, its #3309 holding.
  • BlackRock first reported a position in Starling Oncology Institute, Inc. Common Stock in Q2 2022 and has held it in 16 quarters since.
  • BlackRock's Starling Oncology Institute, Inc. Common Stock position peaked at $13.9M in Q4 2025.
  • 115 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q1 2026.

Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.